# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION

**Washington, D.C. 20549**

---

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 12, 2011**

---

# AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

| **Nevada** | **000-21846** | **13-3632859** |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

| **8910 University Center Lane, Suite 660**<br>**San Diego, California**<br>(Address of principal executive offices) | **92122**<br>(Zip Code) |
|---|---|

Registrant's telephone number, including area code: **(858) 459-7800**

**Not Applicable**
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

The Registrant reported that today, January 12, 2011, at 2:39 p.m. EST, it made a presentation at the U.S. Department of Health and Human Services BARDA (Biomedical Advanced Research and Development Authority) Industry Day held at the Walter E. Washington Convention Center in Washington, DC. A copy of the investor presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. In addition, the Registrant posted the investor presentation materials to its website (www.aethlonmedical.com) today, January 12, 2011 and can be accessed under the investor relations section of the website.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

| Exhibit No. | Description |
|---|---|
| 99.1 | Investor Presentation Materials |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AETHLON MEDICAL, INC.**
(Registrant)

Date: January 12, 2010

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

**EXHIBIT INDEX**

| Exhibit No. | Description |
| --- | --- |
| 99.1 | Investor Presentation Materials |

Exhibit 99.1


aethlon
MEDICAL, INC.
U.S. Department of Health and Human Services
BARDA Industry Day Presentation
Washington, DC
January 12, 20100
James A. Joyce
Chairman, CEO



# Forward Looking Statements

MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE ONLINE AT WWW.SEC.GOV OR WWW.AETHLONMEDICAL.COM



# A Broad-Spectrum Antiviral Platform Technology

# The BARDA Strategic Objectives

- To identify and support the development of innovative broad-spectrum:
  - Countermeasures
  - Technologies
  - Platforms
- Strategies that address traditional, enhanced, emerging, and advanced threats
- Adjunct or adjuvant therapies that improve countermeasure performance


# The Hemopurifier®

The first medical device to selectively remove infectious viruses and immunosuppressive toxins from circulation

# Leverages the established infrastructure of 90,000+ U.S. based dialysis stations



# Additional Infrastructure to Deliver Hemopurifier® Therapy

- CRRT machines already located in hospitals and clinics throughout the U.S.
- Portable pump configurations

# Mechanism of Action

1. Separation of particles below 250nm from the circulatory system

2. Immobilized lectin affinity agents then selectively bind to unique high mannose structures resident on viral glycoproteins that coat viral pathogens




Lectin Binding Site

# Dual Benefit of Action

## Antiviral & Immunotherapeutic

- Antiviral
  - Rapid real-time clearance of infectious viral pathogens
- Immunotherapeutic
  - Fulfills unmet medical need of clearing virally-shed immunosuppressive glycoproteins

aethlon MEDICAL, INC.

# Hemopurifier®

## Selected Quick Facts

- Regulatory Path: Device vs. Drug
- 70 human treatment experiences
- IDE on file with FDA
- GMP manufacturing already established
- Substantial viral load reductions in human HIV and HCV studies
- Follow-on HCV studies initiated
- Proven broad-spectrum capabilities against bioterror and pandemic threats

aethlon MEDICAL, INC.

## *In Vitro* Confirmations Against Bioterror and Pandemic Threats

| Virus | Collaborator |
|---|---|
| Ebola | USAMRIID/CDC |
| Dengue | NIV/WHO |
| Lassa | SFBR |
| West Nile | Battelle |
| H5N1 Avian | Battelle |
| 1918-r Spanish Flu | Battelle |
| 2009 H1N1 Swine | Battelle |
| Monkey Pox | Battelle |

# The Hemopurifier® improves public health emergency preparedness against:

- Traditional Threats
- Enhanced Agents
- Emerging Pathogens
- Advanced Agents

aethlon MEDICAL, INC.

"The Aethlon Hemopurifier® is the only strategy to address the breadth of pathogens that could be weaponized as agents of bioterrorism."

Ken Alibek
First Deputy Director of Biopreparat

# Traditional Threats

Known naturally occurring threats such as
Smallpox, Ebola, Marburg, Lassa

- The Hemopurifier® serves as an adjunct to improve the benefit of established and candidate treatment strategies

- The Hemopurifier® provides a first-line countermeasure strategy against threats not addressed by drug or vaccines

aethlon MEDICAL, INC.

# Enhanced Agents

Traditional threats that have been genetically modified to enhance virulence or circumvent drug and vaccine therapies

- The Hemopurifier® serves as a first-line countermeasure against enhanced agents
- Provides adjunct strategy to strengthen benefit of therapies proven safe and effective against similar pathogen threats
- Assists in characterization of enhanced agents

aethlon MEDICAL, INC.

# Emerging Pathogens

Previously unrecognized pathogens that occur naturally such as SARS or future strains of pandemic influenza

- The Hemopurifier® is a candidate first-line countermeasure against emerging pathogens
- Provides adjunct strategy to strengthen benefit of therapies proven safe and effective against similar pathogen threats
- Assists in early characterization of emerging pathogen threats

aethlon MEDICAL, INC.

# Advanced Agents

Novel pathogen artificially engineered to bypass traditional drug and vaccine countermeasures or enhance disease severity

- The Hemopurifier® represents the sole first-line treatment strategy against advanced agents
- Assists in early characterization of advanced agents

aethlon MEDICAL, INC.

The Hemopurifier® also provides a therapeutic mechanism to address at-risk populations for whom drug and vaccine therapies may be contraindicated

- Immunocompromised
- Children
- Pregnant women
- Senior Citizens

aethlon MEDICAL, INC.

# Stockpile Implications

- > 4 year shelf life
- Refrigeration not required
- Therapeutic demand in HCV, HIV, and cancer provides replenishing FIFO stockpile

aethlon MEDICAL, INC.

# Selected Examples of Therapeutic Filtration

- Kidney dialysis
- Hepatitis-C Virus
- Marburg Plasmapheresis (1990)
- Anthrax Toxin Plasmapheresis (2001)

aethlon MEDICAL, INC.

# 2001 Anthrax Survivor

"It's hard to say what saved me, but one of the things was plasmapheresis. Honestly, without it, I would be dead."

Leroy Richmond
Anthrax infected postal worker

# An Adaptable Platform Technology

- The Hemopurifier® provides a platform for multi-use product development and manufacture
- Interchanging affinity agents within our core Hemopurifier® cartridge expands targets beyond viral threats
- Bacterial threats such as Anthrax could be addressed through immobilization of corresponding anti-toxin antibodies or binding agents
- Radiological threats could be addressed through immobilization of corresponding chelating agents(s)

# Conclusions

- The Hemopurifier® fulfills BARDA's strategy objectives
- It is an innovative broad-spectrum medical countermeasure
- Offers a strategy to address traditional, enhanced, emerging, and advanced threats
- Serves as an adjunct to enhance the benefit of drug and vaccine countermeasures

# Conclusion


The Aethlon Hemopurifier® represents the most advanced broad-spectrum countermeasure against bioterror and emerging pandemic threats

aethlon MEDICAL, INC.

8910 University Center Lane, Suite 660

San Diego, CA. 92122

www.AethlonMedical.com



# Presenter Information

Jim Joyce

Chairman, CEO

Aethlon Medical, Inc.

(858) 459-7800 x301

jj@aethlonmedical.com